- Home
- KTTA vs XNCR Comparison
KTTA vs XNCR Comparison
Compare KTTA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KTTA | XNCR |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 1.1B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | KTTA | XNCR |
|---|---|---|
| Price | $1.13 | $16.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.00 | ★ $22.44 |
| AVG Volume (30 Days) | ★ 21.6M | 738.7K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $0.28 | $6.92 |
| 52 Week High | $3.85 | $26.59 |
Technical Indicators
Market Signals| Indicator | KTTA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 53.33 |
| Support Level | $1.09 | $16.58 |
| Resistance Level | $1.23 | $17.62 |
| Average True Range (ATR) | 0.24 | 0.96 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 46.55 | 28.83 |
Price Performance
Historical ComparisonAbout KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.